July 1, 2024
17,25% más pacientes logran control del prurito ocular con olopatadina al 0,7% Vs al 0,2%2
Referencias
1.IQVIA e INVIMA, revisado 31 de Mayo 2023
2.McLaurin E, Narvekar A, Gomes P, Adewale A, Torkildsen G. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjuntivitis Using the Conjunctival Allergen ChallengeModel. Cornea. 2015:34(10):1245-1251.doi:10.1097/ICO.0000000000000562.
